Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) for Patients-3-Year Follow-Up of Patients with Chronic Kidney Disease.
Rumen FilevMila LyubomirovaBoris BogovKrassimir KalinovJulieta HristovaDobrin SvinarovAlexander GarevLionel RostaingPublished in: Biomedicines (2024)
Post-acute sequelae of SARS-CoV-2 (PASC) is a significant health concern, particularly for patients with chronic kidney disease (CKD). This study investigates the long-term outcomes of individuals with CKD who were infected with COVID-19, focusing on their health status over a three-year period post-infection. Data were collected from both CKD and non-CKD patients who survived SARS-CoV-2 infection and were followed for three years as part of a research study on the impact, prognosis, and consequences of COVID-19 infection in CKD patients. In this prospective cohort study, we analyzed clinical records, laboratory findings, and patient-reported outcomes assessed at intervals during follow-up. The results indicated no permanent changes in renal function in any of the groups analyzed, although patients without CKD exhibited faster recovery over time. Furthermore, we examined the effect of RAAS-blocker therapy over time, finding no influence on PASC symptoms or renal function recovery. Regarding PASC symptoms, most patients recovered within a short period, but some required prolonged follow-up and specialized post-recovery management. Following up with patients in the post-COVID-19 period is crucial, as there is still insufficient information and evidence regarding the long-term effects, particularly in relation to CKD.
Keyphrases
- end stage renal disease
- chronic kidney disease
- sars cov
- patient reported outcomes
- newly diagnosed
- ejection fraction
- healthcare
- peritoneal dialysis
- coronavirus disease
- stem cells
- physical activity
- machine learning
- bone marrow
- palliative care
- patient reported
- social media
- cell therapy
- acute respiratory distress syndrome
- climate change